Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
11/2002
11/28/2002US20020177605 3-substituted isoquinolin-1-yl derivatives
11/28/2002US20020177587 Treating sexual dysfunction including erectile dysfunction, diabetes melitus, gastrointestinal disorders, including gastric paresis and cardiovascular disorders; cyclic guanosine 3',5'-monophosphate (cGMP)
11/28/2002US20020177544 Adenoviral transfer vector for the gene transport of a dna sequence
11/28/2002US20020177213 Tissue plasminogen activator-like protease
11/28/2002US20020176887 Methods of delivery of cetyl myristoleate
11/28/2002US20020176847 Administering to a mammal viral vectors for treating and preventing atherosclerosis, osteoporosis, cardiovascular disease, Alzheimer's disease, diabetes mellitus, infectious diseases, cancer, and inherited disorders
11/28/2002US20020176818 Radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid
11/28/2002DE10125478A1 Treatment or prophylaxis of arterial thrombosis, using 5-quinolinesulfonylamino-benzimidazole derivatives having combined thrombin inhibiting and fibrinogen receptor inhibiting action
11/28/2002DE10124867A1 New substituted (hetero)aryl-alkenes or -alkynes, used as thrombin inhibitors, serine protease inhibitors, antithrombotic agents and intermediates
11/28/2002DE10123505A1 New immunoconjugate comprising egg yolk immunoglobulin Y, useful for treating e.g. inflammation or infection, is derived from specific pathogen-free hens
11/28/2002CA2448120A1 Muscle-specific expression vectors
11/28/2002CA2448022A1 Compositions for protein delivery via the pulmonary route
11/28/2002CA2447940A1 Urazole compounds useful as anti-inflammatory agents
11/28/2002CA2447488A1 Bicyclic inhibitors of factor xa
11/28/2002CA2446734A1 Antibodies against tumor necrosis factor delta (april)
11/28/2002CA2445631A1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002CA2444955A1 Inactivation of genes of the mep pathway
11/28/2002CA2441801A1 Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
11/28/2002CA2427619A1 Pharmaceutically active isoindoline derivatives
11/28/2002CA2410628A1 Carbamic acid esters
11/28/2002CA2410627A1 Glycinamides
11/27/2002EP1259625A2 18232, a dual specificity phosphatase
11/27/2002EP1259621A2 Lipid metabolism enzymes
11/27/2002EP1259612A2 G-protein coupled receptor related polypeptides
11/27/2002EP1259611A2 G-protein coupled receptors
11/27/2002EP1259605A2 Mutated cyclin g1 protein
11/27/2002EP1259595A2 Integrin antagonists
11/27/2002EP1259527A1 35 human secreted proteins
11/27/2002EP1259512A1 Pteridine compounds for the treatment of psoriasis
11/27/2002EP1259510A2 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
11/27/2002EP1259508A1 Novel biarylcarboxamides
11/27/2002EP1259506A1 Pyrazinone thrombin inhibitors
11/27/2002EP1259504A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents
11/27/2002EP1259492A1 Substituted piperazine derivatives as mtp inhibitors
11/27/2002EP1259488A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors
11/27/2002EP1259485A2 BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
11/27/2002EP1259260A1 Combination therapy for the treatment of inflammatory and respiratory diseases
11/27/2002EP1259233A1 Modulation of bone formation
11/27/2002EP1259223A1 Protein matrix materials, devices and methods of making and using thereof
11/27/2002EP1059931B1 Utilization of cd137 in order to promote the proliferation of peripheral monocytes
11/27/2002EP0929547B1 Benzamidine derivatives substituted by cyclic amino acid or cycl ic hydroxy acid derivatives and their use as anti-coagulants
11/27/2002CN1382214A Novel protein derived from agkistrodon saxatilis emelianov and process for preparing the same
11/27/2002CN1382146A Imidazole derivatives asphosphodiesterase VII inhibitors
11/27/2002CN1382144A Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
11/27/2002CN1382143A Inhibitors of alpha L beta 2 mediated cell adhesion
11/27/2002CN1382125A Bicycle vasporession agonists
11/27/2002CN1382124A Bicycle androgen and progesterone receptor modulator compounds and methods
11/27/2002CN1382122A Pyrrole derivatives as phosphodiesterase VII inhibitors
11/27/2002CN1382118A Biocyclic amino acids aspharmaceutical agents
11/27/2002CN1382052A Use of dipyridazole or mopidamol in the manufacture of a medicament for treatment and prevention of fibrin-dependent microcirculation disorders
11/27/2002CN1381465A Gene configuration, preparing process and usage of antibacterial peptide
11/27/2002CN1094977C Polysaccharides having high iduronic acid content
11/27/2002CN1094931C Antithrombotic organic nitrates
11/26/2002US6486305 Method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3
11/26/2002US6486205 Mixture of primary fatty acids obtained from sugar cane wax
11/26/2002US6486154 (Hetero) aryl-sulfonamide derivatives, their preparation and their use as factor XA inhibitors
11/26/2002US6486137 Oligosaccharide mixtures having antithrombotic activity
11/26/2002US6486129 Antithrombotic compounds
11/26/2002US6486126 Antioxidant activity in SDG metabolites
11/26/2002US6486123 Low oxygen affinity mutant hemoglobins
11/26/2002US6486122 Methods of increasing body weight in a subject by administering TGF-α
11/26/2002US6485755 Methods of using electron active compounds for managing cancer
11/26/2002CA2103580C Orthomolecular method of treating sickle cell disease
11/26/2002CA2073734C Humane thrombine concentrate preparation process for therapeutic use
11/22/2002WO2003101942A1 Amidine substituted aryl and heteroaryl derivatives with an antithrombotic and factor xa inhibiting action
11/22/2002WO2001090079A2 Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists
11/22/2002CA2445571A1 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use thereof as pharmaceutical compositions
11/22/2002CA2410304A1 Novel carbamates and ureas production and use thereof as endothelin receptor antagonists
11/21/2002WO2002092827A2 Corona-virus-like particles comprising functionally deleted genomes
11/21/2002WO2002092817A1 Functions for d52 and ra006 nucleic acids and polypeptides
11/21/2002WO2002092808A1 Random gene unidirectional antisense library
11/21/2002WO2002092807A1 Unigene unidirectional antisense library
11/21/2002WO2002092781A2 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002WO2002092759A2 Molecules for disease detection and treatment
11/21/2002WO2002092616A1 Antisense permeation enhancers
11/21/2002WO2002092614A1 Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
11/21/2002WO2002092593A1 4-(4-pyridazinyl)pyrazole derivatives
11/21/2002WO2002092588A2 Aromatic sulfone hydroxamates and their use as protease inhibitors
11/21/2002WO2002092576A1 Diarylurea derivatives useful as anti-inflammatory agents
11/21/2002WO2002092568A1 5-cyano-1h-indole derivatives as antagonists of the interleukine-8 receptors
11/21/2002WO2002092567A1 Novel 5-phenyl-1h-indole derivatives as antagonists of interleukine-8 receptors
11/21/2002WO2002092558A1 Polythiourea lipid derivatives
11/21/2002WO2002092136A2 Immunoconjugates made of egg-yolk antibodies (igy), production and use thereof in diagnoses and therapy
11/21/2002WO2002092109A1 Herbal composition and its use
11/21/2002WO2002092090A1 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
11/21/2002WO2002092087A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
11/21/2002WO2002092075A2 Therapeutic delivery of carbon monoxide
11/21/2002WO2002092069A1 Permeation enhancers
11/21/2002WO2002092064A2 Therapeutic method for inducing tolerance
11/21/2002WO2002092016A2 Therapeutic use of rank antagonists
11/21/2002WO2002092008A2 Use of il-18 inhibitors for the treatement or prevention of sepsis
11/21/2002WO2002092004A2 Use of hmg fragment as anti-inflammatory agents
11/21/2002WO2002081728A3 Quinoline inhibitors of hyak1 and hyak3 kinases
11/21/2002WO2002070507A3 Glycorticoid receptor antagonists for treatment of diabetes
11/21/2002WO2002064148A3 Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
11/21/2002WO2002049649A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
11/21/2002WO2002020091A3 Antithrombotic compositions
11/21/2002WO2001019397A9 Methods and compositions utilizing rad51
11/21/2002US20020173661 Phosphodiesterase-4 (PDE4); thiazole-containing pyridine (N-oxide) compounds; 4-(2-(3,4-Bis(difluoromethoxy)phenyl)-2-(5-(2-(1-hydroxy-1 -methyl)ethyl)thiazolyl)ethyl)pyridine N-oxide for example
11/21/2002US20020173656 Guanidine and amidine derivatives as factor Xa inhibitors
1 ... 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 ... 671